U.S. Defense Secretary Pete Hegseth ordered annual testosterone-deficiency screening for active-duty and reserve service members age 30 and older, a policy change aimed at maintaining military readiness that has immediately drawn skepticism from medical professionals. According to reports from militarytimes.com and theguardian.com, medical experts warn the mandate lacks concrete scientific backing and could increase service members’ risk of infertility or other adverse health consequences if testosterone is prescribed inappropriately.
Pentagon Rationale and Voluntary Treatment Goals
Defense Secretary Pete Hegseth stated that the new testing program will ensure troops have optimal hormone levels to operate at their absolute best. According to the reporting, the initiative is designed to improve service members’ resilience, longevity, and physical performance to safeguard combat readiness. Hegseth added that testing will be accompanied by advisory support to help soldiers make informed choices about treatment, and participation in treatment will be voluntary.
Medical Community Concerns Over Screening Mandate
Five of six men’s health experts contacted by Reuters expressed confusion regarding the announcement, warning that blanket screening for personnel aged 30 and older may lead to unnecessary and potentially harmful interventions. Four of those doctors emphasized that no solid evidence suggests routine screening across this demographic will improve combat readiness.
Dr. Kevin McVary, a urologist on the medical advisory board of telehealth platform Rugiet, noted that while patients treated for low testosterone report improvements in cognitive alertness and stamina, that evidence stems exclusively from individuals treated because they were already symptomatic. McVary cautioned that providing testosterone to asymptomatic individuals leads to overtreatment and associated medical risks.
Dr. Haleem Mohammed, chief medical officer of men’s wellness clinic network Gameday Health, pointed out that while testosterone levels naturally decline by roughly 1% per year starting between ages 30 and 40, age 30 itself is not an appropriate clinical threshold for routine screening. Dr. Ugis Gruntmanis, an endocrinologist at Dartmouth Hitchcock Medical Center, observed that because most replacement studies focus on older populations, the mandate presents an opportunity to gather data on younger men. However, Gruntmanis warned that implementing widespread screening ahead of preliminary study data puts the cart before the horse.
Guidelines and Cardiovascular Considerations
Major medical organizations, including the American Urological Association and the Endocrine Society, advise testosterone supplementation strictly for patients with confirmed deficiency accompanied by symptoms such as fatigue, reduced libido, erectile dysfunction, decreased muscle mass, and low bone density.
The policy rollout follows recent regulatory updates involving testosterone labeling. The U.S. Food and Drug Administration previously revised testosterone labels to remove warnings regarding increased risks of heart attack or stroke. That decision relied in part on a study led by Dr. Steven Nissen of the Cleveland Clinic, which evaluated more than 5,200 men aged 45 to 80 with low testosterone and high cardiovascular risk. Nissen noted that study participants experienced higher rates of bone fractures and atrial arrhythmia, an abnormal heart rhythm—findings that could carry direct implications for military populations.
Keep reading